RetinaCME
LECTURECME

Progressive Pathways in Treating Neovascular Retinal Disease: Exploring Tie2

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Carl D. Regillo, MD, FACS; Charles C. Wykoff, MD, PhD
Release Date: 1/15/2019Expiration Date: 1/14/2020
Credit Type: CMENumber of Credits: 1.25
Content Type: LectureProvider:
The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapy into management algorithms for the treatment of patients with neovascular retinal disease have revolutionized outcomes in these patients. However, clinical studies have demonstrated that around two thirds of treated patients have a suboptimal or no response to anti-VEGF treatment regimens demonstrating a need for the identification of new molecular targets for therapeutic intervention. Currently, molecular pathways that are involved in abnormal angiogenesis and increased vascular permeability are being targeted in clinical studies. One such pathway is the Tie2 angiogenic pathway, and promising novel agents that target this pathway are currently being assessed for the treatment of neovascular disease. In this educational activity, experts in the field will review the need for alternatives to anti-VEGF monotherapy, discuss pathophysiologic mechanisms behind the Tie2 signaling pathway, evaluate the most recent efficacy and safety data for novel agents targeting the Tie2 angiogenic pathway in neovascular disease, as well as provide insight into how these agents may modify the paradigm of current treatment algorithms.